Effect of omeprazole and sucralfate on prepyloric gastric ulcer. A double blind comparative trial and one year follow up

• Published in: Gut Vol. 35; no. 6; pp. 837 - 840
• Main Authors: Sørensen, H T, Rasmussen, H H, Balslev, I, Boesby, S, Boné, J, Kruse, A, Rasmussen, S N
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group Ltd and British Society of Gastroenterology 01.06.1994; BMJ; BMJ Publishing Group LTD
• Subjects: Adult; Aged; Biological and medical sciences; Digestive system; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Medical sciences; Middle Aged; Omeprazole - therapeutic use; Pharmacology. Drug treatments; Stomach Ulcer - drug therapy; Sucralfate - therapeutic use; Time Factors; Treatment Outcome; Human; Stomach; Chemotherapy; Treatment; Antisecretory agent; Evolution; Ulcer; Antiulcer agent; Antiacid; Comparative study
• ISSN: 0017-5749; 1468-3288; 1458-3288
• DOI: 10.1136/gut.35.6.837

This study compared healing rates, relief of symptoms, frequency of adverse events, and proportion of patients in remission after one year follow up in 104 patients with active prepyloric ulcer during treatment with 40 mg omeprazole once daily or 2 g sucralfate twice daily, using a randomised double blind controlled trial. Healing rates after two, four, and six weeks were (omeprazole/sucralfate) 49%/23%; 83%/59%; 90%/70% respectively. After two weeks, omeprazole was more efficient than sucralfate in relief of daytime and nocturnal epigastric pain, nausea, and heartburn. The proportion of patients in remission after one year follow up was significantly higher in the omeprazole group (p < 0.01). Of the healed patients ulcers recurred in 36% in the omeprazole group and in 46% in the sucralfate group. It is concluded that the ulcer healing rate was higher and symptom relief was more pronounced in the omeprazole group compared with the sucralfate group, and that more patients were still in remission after a one year follow up period.